< Back to Goodman & Gilman's
7/9/07
Pharmacogenetic Targeting of Cardiovascular Drugs
by Michael R. Bristow, MD, PhD
S. Gilbert Blount Professor of Medicine
Co-Director, Colorado University Cardiovascular Institute
University of Colorado Health Sciences Center
Denver and Aurora, Colorado
|
 |
Start the lecture (51 minutes, 31 seconds)
(Flash Player 8 required. Download free Flash Player)
About this lecture:
This Grand Rounds was recorded on January 11, 2007 at the University of Utah as part of the 2007-2008, T.J. Tsagaris Memorial Lectureship awarded to Dr. Bristow. The recording has been edited for use as part of the GGOL Grand Rounds series. Dr. Bristow is a pioneer in the development and use of beta-adrenergic blocking agents for the treatment of chronic heart failure.
This lecture looks at pharmacogenetic targeting of cardiovascular drugs as a treatment option in heart failure, using as its premise altered gene expression as a leading cause of heart failure.
 Printable View
Lecture related to:
Chapter 7: Pharmacogenetics
Chapter 12: Adrenergic Agonists and Antagonists
Chapter 28: Pharmacotherapy of Congestive Heart Failure
Chapter 29: Anti-Arrhythmic Drugs
Your feedback:
Would you like to see more from Goodman & Gilman's Grand Rounds? Let us know what you thought about this lecture and what other topics you would like to see in future Grand Rounds.
|
|
|
|